Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. Its preclinical product candidates include LP659 and LP143, which focuses on developing therapies for multiple neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.
Revenue of Longboard Pharmaceuticals, Inc. (LBPH)
Revenue in 2023 (TTM): $
According to Longboard Pharmaceuticals, Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Longboard Pharmaceuticals, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-5,000 | $-56,754,000 | $-54,422,000 | $-54,422,000 |
| 2022 | $ | $-5,000 | $-44,793,000 | $-43,945,000 | $-43,092,000 |
| 2021 | $ | $-1,000 | $-27,838,000 | $-27,797,000 | $-27,733,000 |
| 2020 | $ | $ | $-14,400,000 | $-14,400,000 | $-14,400,000 |